NIH budget cuts could reduce new drug approvals by 4.5%, or two drugs annually over 30 years. A nine-month FDA review delay could lead to 2% fewer drug approvals in the long term. September’s ...
GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think ...
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...
New Taipei City, Taiwan, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing ...
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry ...
As China's new drug R&D enters the "deep waters" of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have ...
When companies file hundreds of patents for a single drug, affordable versions can remain out of reach for years. pilli/iStock via Getty Images Plus Pharmaceutical innovation saves lives. But not ...
Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the ...
LONDON, Jan. 9, 2026 /PRNewswire/ -- M&G Investments (M&G) today announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pioneering ...
Some of the most ambitious cancer science is happening in a disease few outside of oncology can name, and it’s revealing a future where cancer is no longer a death sentence. Multiple myeloma (MM) is a ...
The goal of this collaborative is to examine and highlight the bottlenecks to drug research and development (R&D) for highly prevalent chronic diseases and develop a set of key considerations and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results